Remove 2003 Remove Drugs Remove Packaging Remove Research
article thumbnail

The Economics of Investigational Device Exemption (IDE) Studies: What You Need to Know About Medicare Coverage

The Premier Consulting Blog

Charging for Investigational Devices in IDE Studies Under IDE regulations, sponsors are allowed to charge for an investigational device provided that the charge does not exceed an amount necessary to recover the costs of manufacture, research, development and handling of the device. [2] Resources [1] US Food and Drug Administration.

article thumbnail

CHMP positive opinion recommending approval of Benlysta for adult patients with active lupus nephritis

The Pharma Data

This CHMP opinion follows the recent label expansion by the US Food and Drug Administration to include LN. Make patients aware of potential risk of hypersensitivity reactions (day of, or several days after infusion, including signs/symptoms and recurrence) and provide package leaflet each time Benlysta administered.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Article FDA Thank You FDA updates set the stage for broader use of harmonized standards for safety reporting

Agency IQ

When the document was taken back to the drawing board again in 2003, it remained on hold for more than a decade until a final version was agreed upon in 2012, with the FDA officially adopting it in 2014. While the SRP could be used to submit information on drugs and biological products, the only exception was for vaccines.

FDA 40
article thumbnail

Article FDA Thank You FDA unveils long-awaited Patient Medication Information proposed rule

Agency IQ

FDA unveils long-awaited Patient Medication Information proposed rule Since 2017, the FDA has been working on a proposal to create a new type of patient-focused labeling for certain outpatient drug products that would be specifically targeted for patient use. The FDA recently concluded its work on a proposed rule focused on PMI.

FDA 40
article thumbnail

Analysis Chemical Thank You What we expect the EPA to do in November 2023

Agency IQ

The current Primary Magnesium Refining NESHAP was promulgated pursuant to CAA section 112(d) on October 10, 2003. The Rubber Tire Manufacturing NESHAP, subpart XXXX, was promulgated pursuant to section 112(d) of the Clean Air Act (CAA) on July 9, 2002, with corrections promulgated on March 12, 2003.

article thumbnail

Analysis Chemical Thank You What we expect the EPA to do in December 2023

Agency IQ

The current Primary Magnesium Refining NESHAP was promulgated pursuant to CAA section 112(d) on October 10, 2003. This package would propose updates to the alternative work practice as appropriate based on the review and address the issues raised for reconsideration. 2020) (LEAN).

article thumbnail

Analysis Chemical Thank You What we expect the EPA to do in April 2024

Agency IQ

The Iron and Steel Manufacturing Facilities NESHAP was promulgated pursuant to section 112(d) of the Clean Air Act on May 20, 2003, and subsequently amended on July 13, 2006. section 7412(d)(6). The residual risk and technology review (RTR) was promulgated pursuant to CAA sections 112(f) and 112(d)(6) on July 13, 2020.